|
|
OSUCCC
 |
John C. Byrd, M.D.
Assoc. Director for Translational Research
Professor
College of Medicine
Internal Medicine - Hematology/Oncology
B302 Starling-Loving
320 W. 10th Avenue Columbus,OH. 43210
o |
(614) 293-7509 |
f |
(614) 293-7526 |
|
Programs
|
 |
|
|
Current Publications
|
|
Cancer Chemother Pharmacol in press: , 2009
|
|
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
|
|
Ramaswamy B, Bekaii-Saab T, Schaaf LJ, Lesinski GB, Lucas DM, Young DC, Ruppert AS, Byrd JC, Culler K, Wilkins D, Wright JJ, Grever MR, Shapiro CL
|
|
|
in press: , 2009
|
|
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
|
|
Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC
|
|
|
Leukemia 23(5): 912-8, 2009
|
|
A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
|
|
Woyach JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C, Lucas DM, Wei L, Caligiuri MA, Byrd JC
|
|
|
in press: , 2009
|
|
Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.
|
|
Lin TS, Naumovski L, Lecane PS, Lucas MS, Moran ME, Cheney C, Lucas DM, Phan SC, Miller RA, Byrd JC
|
|
|
Proc Natl Acad Sci U S A 106(32): 13433-8, 2009
|
|
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia.
|
|
Chen SS, Raval A, Johnson AJ, Hertlein E, Liu TH, Jin VX, Sherman MH, Liu SJ, Dawson DW, Williams KE, Lanasa M, Liyanarachchi S, Lin TS, Marcucci G, Pekarsky Y, Davuluri R, Croce CM, Guttridge DC, Teitell MA, Byrd JC, Plass C
|
|
|
Clin Lymphoma Myeloma 9 Suppl 3: S179-85, 2009
|
|
Flavopiridol in chronic lymphocytic leukemia: a concise review.
|
|
Christian BA, Grever MR, Byrd JC, Lin TS
|
|
|
50(10): 1589-96, 2009
|
|
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
|
|
Byrd JC, Byrd JC, Peterson BL, Rai KR, Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, Gockerman J, Nattam S, Larson RA
|
|
|
Biol Blood Marrow Transplant 15(11): 1422-30, 2009
|
|
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
|
|
Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM
|
|
|
in press: , 2009
|
|
Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia.
|
|
Sanchez-Aguilera A, Rattmann I, Drew DZ, Müller LU, Summey V, Lucas DM, Byrd JC, Croce CM, Gu Y, Cancelas JA, Johnston P, Moritz T, Williams DA
|
|
|
Blood 113(3): 535-7, 2009
|
|
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
|
|
Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N, Jelinek DF, Tschumper RC, Secreto CR, Lin TS, Grever MR, Shanafelt TD, Zent CS, Call TG, Heerema NA, Lozanski G, Byrd JC, Lucas DM
|
|
|
Blood 113(25): 6411-8, 2009
|
|
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
|
|
Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, Bloomfield CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci G
|
|
|
in press: , 2009
|
|
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
|
|
Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S
|
|
|
J Clin Oncol in press: , 2009
|
|
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease.
|
|
Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, Byrd JC
|
|
|
Br J Haematol 147(4): 507-14, 2009
|
|
Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.
|
|
Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S, Kassis J, Davis M, Bonfils C, Dubay M, Dumouchel J, Drouin M, Lucas DM, Martell RE, Byrd JC
|
|
|
Br J Haematol 146(6): 660-4, 2009
|
|
Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.
|
|
Shanafelt TD, Byrd JC, Laplant B, Zent CS, Call T, Secreto C, Grever MR, Lin TS, Kay NE
|
|
|
Leuk Lymphoma 50(3): 349-56, 2009
|
|
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.
|
|
Blum KA, Hamadani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM, Byrd JC
|
|
|
in press: , 2009
|
|
Targeted Delivery of Antisense Oligodeoxynucleotide by Transferrin Conjugated pH-Sensitive Lipopolyplex Nanoparticles: A Novel Oligonucleotide -Based Therapeutic Strategy in Acute Myeloid Leukemia.
|
|
Jin Y, Liu S, Yu B, Godan S, Koh CG, Yang J, Huynh L, Yang X, Pang J, Muthusamy N, Chan K, Byrd JC, Talmon Y, Lee LJ, Lee R, Marcucci G
|
|
|
Br J Haematol 144(6): 848-55, 2009
|
|
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
|
|
Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC
|
|
|
Blood 113(19): 4656-66, 2009
|
|
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.
|
|
Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, Goettl VM, Heerema NA, Lin TS, Lehman A, Zhang X, Jarjoura D, Newman DJ, Byrd JC, Kinghorn AD, Grever MR
|
|
|
PLoS One 4(1): e4208, 2009
|
|
The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma.
|
|
Joshi T, Ganesan LP, Cheney C, Ostrowski MC, Muthusamy N, Byrd JC, Tridandapani S
|
|
|
Mol Pharm 6(1): 221-30, 2009
|
|
Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.
|
|
Yang X, Koh CG, Liu S, Pan X, Santhanam R, Yu B, Peng Y, Pang J, Golan S, Talmon Y, Jin Y, Muthusamy N, Byrd JC, Chan KK, Lee LJ, Marcucci G, Lee RJ
|
|
|
Proteomics 9(5): 1197-206, 2009
|
|
Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia.
|
|
Su X, Lucas DM, Zhang L, Xu H, Zabrouskov V, Davis ME, Knapp AR, Young DC, Payne PR, Parthun MR, Marcucci G, Grever MR, Byrd JC, Freitas MA
|
|
|
Int J Pharm 365(1-2): 170-4, 2008
|
|
A novel liposomal formulation of flavopiridol.
|
|
Yang X, Zhao X, Phelps MA, Piao L, Rozewski DM, Liu Q, Lee LJ, Marcucci G, Grever MR, Byrd JC, Dalton JT, Lee RJ
|
|
|
Clin Cancer Res 14(2): 569-78, 2008
|
|
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
|
|
Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, Byrd JC
|
|
|
Clin Cancer Res 14(8): 2444-9, 2008
|
|
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
|
|
Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van LE, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G
|
|
|
Blood 111(4): 2364-73, 2008
|
|
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
|
|
Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu LC, Marcucci G
|
|
|
J Clin Invest 118(7): 2427-37, 2008
|
|
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
|
|
Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, Byrd JC, Gribben JG
|
|
|
Blood 113(12): 2637-45, 2008
|
|
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
|
|
Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Booker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT
|
|
|
Blood 111(9): 4427, 2008
|
|
CLL and activated NF-kappaB: living partnership.
|
|
Hertlein E, Byrd JC
|
|
|
Cancer Biother Radiopharm 22(5): 713-4; author reply 715-7, 2008
|
|
Community-based phase II trial of PCR for CLL/SLL patients.
|
|
Kay NE, Shanafelt TD, Byrd JC, Grever MR
|
|
|
J Clin Oncol 26(14): 2244-5, 2008
|
|
Comprehensive single nucleotide polymorphism study supports the role of MDM2 in p53-competent chronic lymphocytic leukemia.
|
|
Lucas DM, Byrd JC
|
|
|
J Clin Oncol 25(35): 5624-9, 2008
|
|
Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.
|
|
Blum KA, Young DC, Broering S, Lucas MS, Fischer B, Lin TS, Grever MR, Byrd JC
|
|
|
Ther Drug Monit in press: Epub 2008, 2008
|
|
Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma.
|
|
Liu Q, Farley KL, Johnson AJ, Muthusamy N, Hofmeister CC, Blum KA, Schaaf LJ, Grever MR, Byrd JC, Dalton JT, Phelps MA
|
|
|
J Chromatogr B Analyt Technol Biomed Life Sci 868(1-2): 110-5, 2008
|
|
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule.
|
|
Phelps MA, Rozewski DM, Johnston JS, Farley KL, Albanese KA, Byrd JC, Lin TS, Grever MR, Dalton JT
|
|
|
Leuk Res 31(12): 1737-40, 2008
|
|
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.
|
|
Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC, Lucas DM
|
|
|
Blood 111(6): 3190-9, 2008
|
|
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.
|
|
Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX, Viatchenko-Karpinski S, Ruppert AS, Byrd JC, Kuppusamy P, Crouser ED, Grever MR
|
|
|
Curr Opin Oncol 19(6): 573-8, 2008
|
|
Flavopiridol in the treatment of chronic lymphocytic leukemia.
|
|
Christian BA, Grever MR, Byrd JC, Lin TS
|
|
|
Blood 111(1): 275-84, 2008
|
|
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
|
|
Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, Muthusamy N, Byrd JC
|
|
|
J Clin Invest 117(9): 2408-21, 2008
|
|
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
|
|
Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D
|
|
|
J Clin Oncol 26(15): 2519-25, 2008
|
|
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
|
|
Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang DS, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen CS, Byrd JC
|
|
|
Blood 111(9): 4723-30, 2008
|
|
IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro.
|
|
Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S, Zhang X, Lehman A, Jarjoura D, Carson WE, Kindsvogel W, Cheney C, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC
|
|
|
Blood 112(13): 5180-9, 2008
|
|
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
|
|
Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC
|
|
|
J Pharm Sci 97(4): 1508-18, 2008
|
|
Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.
|
|
Zhao X, Wu J, Muthusamy N, Byrd JC, Lee RJ
|
|
|
Blood 111(3): 1594-602, 2008
|
|
Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.
|
|
Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J
|
|
|
Br J Haematol 139(5): 744-52, 2008
|
|
Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes.
|
|
Plass C, Byrd JC, Raval A, Tanner SM, de la Chapelle A
|
|
|
J Natl Compr Canc Netw 6(4): 356-421, 2008
|
|
Non-Hodgkin's lymphomas.
|
|
Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM
|
|
|
Blood 111(6): 3137-3144, 2008
|
|
Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3
|
|
Widhopf GF, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, Keating MJ, Gribben JG, Rai KR, Kipps TJ
|
|
|
Best Pract Res Clin Haematol 20(3): 545-56, 2008
|
|
Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.
|
|
Grever MR, Lucas DM, Johnson AJ, Byrd JC
|
|
|
J Clin Oncol 25(25): 3884-91, 2008
|
|
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
|
|
Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine S, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G
|
|
|
Clin Cancer Res 14(12): 3889-95, 2008
|
|
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
|
|
Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G
|
|
|
Blood 112(5): 1923-30, 2008
|
|
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
|
|
Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ
|
|
|
Br J Haematol 139(5): 837-44, 2008
|
|
Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
|
|
Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas DM, Guster SK, Grever MR, Lin TS, Byrd JC
|
|
|
Blood 113(5): 1002-5, 2008
|
|
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
|
|
Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W
|
|
|
Blood 110(7): 2569-77, 2008
|
|
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.
|
|
Zhao XB, Lapalombella R, Joshi T, Cheny C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kusewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC, Zhao X, Cheney C
|
|
|
J Immunol 181(6): 3784-92, 2008
|
|
TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells.
|
|
Trotta R, Col JD, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J 2nd, Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA
|
|
|
Blood 111(10): 5101-8, 2008
|
|
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.
|
|
Ghia EM, Jain S, Widhopf GF, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ
|
|
|
